Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription


2 Am J Cardiol
5 Ann Thorac Surg
2 Cardiovasc Res
1 Circ Cardiovasc Qual Outcomes
7 Circ Heart Fail
6 Circulation
1 Clin Cardiol
1 Coron Artery Dis
3 Eur Heart J
16 Eur J Heart Fail
3 Int J Cardiol
2 J Am Coll Cardiol
3 J Card Fail
1 J Cardiovasc Pharmacol
3 J Mol Cell Cardiol
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Cardiol

  1. VILLADSEN PR, Horvath-Puho E, Sorensen HT, Schmidt M, et al
    The Interaction Effect of Cardiac and Noncardiac Co-morbidities on Mortality Rates in Patients With Heart Failure.
    Am J Cardiol. 2022 Jul 19. pii: S0002-9149(22)00646.
    PubMed         Abstract available

  2. PATOULIAS D, Papadopoulos C, Fragakis N, Karagiannis A, et al
    Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.
    Am J Cardiol. 2022 Jul 21. pii: S0002-9149(22)00661.

    Ann Thorac Surg

  3. MALICK A, Ning Y, Kurlansky PA, Melehy A, et al
    Development of De Novo Aortic Insufficiency in Patients With HeartMate 3.
    Ann Thorac Surg. 2022;114:450-456.
    PubMed         Abstract available

  4. AKHMEROV A, Ramzy D
    Supporting the Right Heart-Do It Right and Do It Early.
    Ann Thorac Surg. 2022;114:491.

  5. BELLER JP, Mehaffey JH, Wegermann ZK, Grau-Sepulveda M, et al
    Strategies for Mechanical Right Ventricular Support During Left Ventricular Assist Device Implant.
    Ann Thorac Surg. 2022;114:484-491.
    PubMed         Abstract available

  6. CARVAJAL HG, Gooch C, Merritt TC, Fox JC, et al
    Mid-Term Outcomes of Heart Transplantation in Children with Genetic Disorders.
    Ann Thorac Surg. 2022 Jan 7. pii: S0003-4975(22)00016.
    PubMed         Abstract available

  7. JAWAD K, Nozdrzykowski M, Borger MA, Saeed D, et al
    Less Invasive Assist Device Implantation in Patients With History of Previous Cardiac Procedures: How I Teach It.
    Ann Thorac Surg. 2022;114:383-386.

    Cardiovasc Res

  8. JANG AY, Scherer PE, Kim JY, Lim S, et al
    Adiponectin and cardiometabolic trait and mortality: where do we go?
    Cardiovasc Res. 2022;118:2074-2084.
    PubMed         Abstract available

  9. BORLAUG BA, Jensen MD, Kitzman DW, Lam CSP, et al
    Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets.
    Cardiovasc Res. 2022 Jul 26. pii: 6649894. doi: 10.1093.
    PubMed         Abstract available

    Circ Cardiovasc Qual Outcomes

  10. KORSGAARD S, Schmidt M, Maeng M, Jakobsen L, et al
    Long-Term Outcomes of Perioperative Versus Nonoperative Myocardial Infarction: A Danish Population-Based Cohort Study (2000-2016).
    Circ Cardiovasc Qual Outcomes. 2022;15:e008212.
    PubMed         Abstract available

    Circ Heart Fail

  11. BARAN DA, Long A, Lansinger J, Copeland JG, et al
    Donor Utilization in the Recent Era: Effect of Sex, Drugs, and Increased Risk.
    Circ Heart Fail. 2022;15:e009547.
    PubMed         Abstract available

  12. ELLIOTT P, Gundapaneni B, Sultan MB
    Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Circ Heart Fail. 2022;15:e009637.

  13. BALDOVINO S, Costanzo P, Roccatello D
    Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Circ Heart Fail. 2022;15:e009617.

  14. BADR ESLAM R, Ozturk B, Rettl R, Capelle CDJ, et al
    Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy.
    Circ Heart Fail. 2022;15:e008381.
    PubMed         Abstract available

  15. PARK J, Banerjee S, Hong J, Umar S, et al
    Response by Park et al to Letter Regarding Article, "Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular
    Circ Heart Fail. 2022 Jun 29:101161CIRCHEARTFAILURE122008632.

  16. HENRIKSEN PA, Hall P, Oikonomidou O, MacPherson IR, et al
    Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Circ Heart Fail. 2022;15:e009445.
    PubMed         Abstract available

    Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis.
    Circ Heart Fail. 2022;15:e009387.


  18. ABDEL-QADIR H, Akioyamen LE, Fang J, Pang A, et al
    Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study.
    Circulation. 2022 Jun 9:101161CIRCULATIONAHA122058949.
    PubMed         Abstract available

  19. LEE MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, et al
    Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2022;146:364-367.

  20. PANDEY A, Keshvani N, Wang TJ
    Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction?
    Circulation. 2022;146:276-278.

  21. REDDY YNV, Borlaug BA, Gersh BJ
    Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction.
    Circulation. 2022;146:339-357.
    PubMed         Abstract available

  22. ANKER SD, Usman MS, Butler J
    SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Circulation. 2022;146:299-302.

  23. Correction to: Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
    Circulation. 2022;146:e12.

    Clin Cardiol

  24. LIU YX, Chen W, Lin X, Zhu YL, et al
    Initiating ivabradine during hospitalization in patients with acute heart failure: A real-world experience in China.
    Clin Cardiol. 2022 Jul 23. doi: 10.1002/clc.23880.
    PubMed         Abstract available

    Coron Artery Dis

  25. MARCUSOHN E, Reiner Benaim A, Ronen S, Kerner A, et al
    Door to balloon time in primary percutaneous coronary intervention in ST elevation myocardial infarction: every minute counts.
    Coron Artery Dis. 2022;33:341-348.
    PubMed         Abstract available

    Eur Heart J

  26. BUTLER J, Anker SD, Lund LH, Coats AJS, et al
    Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Eur Heart J. 2022 Jul 28. pii: 6651164. doi: 10.1093.
    PubMed         Abstract available

  27. PACKER M
    Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial.
    Eur Heart J. 2022 Jul 28. pii: 6651163. doi: 10.1093.

  28. Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Eur Heart J. 2022 Jul 22. pii: 6649203. doi: 10.1093.

    Eur J Heart Fail

  29. SCHRAGE B, Westermann D
    Enough iron in transcatheter aortic valve implantation already.
    Eur J Heart Fail. 2022;24:1280-1281.

  30. TOMASONI D, Adamo M, Metra M
    July 2022 at a glance: focus on prognosis, devices and valvular heart disease.
    Eur J Heart Fail. 2022;24:1145-1147.

  31. METRA M, Jankowska EA, Pagnesi M, Anker SD, et al
    Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
    Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2630.

  32. CHATUR S, Vaduganathan M, Peikert A, Claggett BL, et al
    Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Jul 27. doi: 10.1002/ejhf.2638.
    PubMed         Abstract available

    Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG.
    Eur J Heart Fail. 2022;24:1237-1238.

  34. MCGURK KA, Halliday BP
    Dilated cardiomyopathy - details make the difference.
    Eur J Heart Fail. 2022;24:1197-1199.

  35. PETUTSCHNIGG J, Edelmann F
    Closing the gap, or the beauty of alleviating our patients' symptoms.
    Eur J Heart Fail. 2022;24:1302-1304.

  36. BORIANI G, Vitolo M, Leyva F
    Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'?
    Eur J Heart Fail. 2022;24:1223-1226.

  37. NAYAK A, Mehra MR
    Global challenges in left ventricular assist device therapy: a tale across two continents.
    Eur J Heart Fail. 2022;24:1316-1318.

  38. ILIADIS C, Kalbacher D, Lurz P, Petrescu AM, et al
    Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:1282-1292.
    PubMed         Abstract available

  39. KVASLERUD AB, Bardan S, Andresen K, Klove SF, et al
    Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.
    Eur J Heart Fail. 2022;24:1269-1279.
    PubMed         Abstract available

  40. PORCARI A, Rossi M, Cappelli F, Canepa M, et al
    Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1227-1236.
    PubMed         Abstract available

  41. JAKUS N, Brugts JJ, Claggett B, Timmermans P, et al
    Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry.
    Eur J Heart Fail. 2022;24:1305-1315.
    PubMed         Abstract available

  42. MIRELIS JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, et al
    Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1183-1196.
    PubMed         Abstract available

  43. MANCA P, Stolfo D, Merlo M, Gregorio C, et al
    Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1171-1179.
    PubMed         Abstract available

  44. STOCKER TJ, Cohen DJ, Arnold SV, Sommer S, et al
    Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy.
    Eur J Heart Fail. 2022;24:1293-1301.
    PubMed         Abstract available

    Int J Cardiol

  45. AREVALO-LORIDO JC, Carretero-Gomez J
    The circular pathway for the improvement of readmitting heart failure patients.
    Int J Cardiol. 2022 Jul 20. pii: S0167-5273(22)01099.

  46. PINTALHAO M, Vasques-Novoa F, Couto-Viana B, Pimentel MJ, et al
    Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort.
    Int J Cardiol. 2022 Jul 20. pii: S0167-5273(22)01106.
    PubMed         Abstract available

  47. CHISHIKI T, Nagatomo Y, Saji M, Takei M, et al
    Divergent effect of blood glucose dysregulation on long-term clinical outcome in acute decompensated heart failure: A reappraisal in contemporary practice.
    Int J Cardiol. 2022 Jul 25. pii: S0167-5273(22)01111.
    PubMed         Abstract available

    J Am Coll Cardiol

  48. ZISIS G, Yang Y, Huynh Q, Whitmore K, et al
    Nurse-Provided Lung and Inferior Vena Cava Assessment in Patients With Heart Failure.
    J Am Coll Cardiol. 2022;80:513-523.
    PubMed         Abstract available

  49. WILEY BM, Borlaug BA, Kane GC
    Lung Ultrasound in Heart Failure: Envisioning Handheld Ultrasound to Empower Nurses and Transform Health Care.
    J Am Coll Cardiol. 2022;80:524-526.

    J Card Fail

  50. CLARK KAA, DeFilippis EM, Morris AA
    Breaking the Bank: The Financial Burden of Living with Heart Failure.
    J Card Fail. 2022 Jul 20. pii: S1071-9164(22)00603.

  51. FELKER GM, Sharma A, Mentz RJ, She L, et al
    A randomized controlled trial of mobile health intervention in patients with heart failure and diabetes.
    J Card Fail. 2022 Jul 23. pii: S1071-9164(22)00649.
    PubMed         Abstract available

  52. DUNLAY SM, Killian JM, Roger VL, Schulte PJ, et al
    Guideline Directed Medical Therapy in Newly Diagnosed Heart Failure with Reduced Ejection Fraction in the Community.
    J Card Fail. 2022 Jul 25. pii: S1071-9164(22)00648.
    PubMed         Abstract available

    J Cardiovasc Pharmacol

  53. YANG G, Gai X, Han M, Gao F, et al
    Aberrant circulating SNHG1 serves as a biomarker to distinguish acute myocardial infarction and construction of a risk model for secondary heart failure.
    J Cardiovasc Pharmacol. 2022 Jul 11. pii: 00005344-990000000-00043.

    J Mol Cell Cardiol

  54. GHEBLAWI M, de Oliveira AA, Williams VR, John R, et al
    An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1-7 rescue of the diabetic phenotype.
    J Mol Cell Cardiol. 2022;169:10-12.

  55. GUO X, Chen Y, Liu Q
    Necroptosis in heart disease: Molecular mechanisms and therapeutic implications.
    J Mol Cell Cardiol. 2022;169:74-83.
    PubMed         Abstract available

  56. THARP CA, McKinsey TA
    Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF.
    J Mol Cell Cardiol. 2022;169:111-112.

    PLoS One

  57. HAN JH, McNaughton CD, Stubblefield WB, Pang PS, et al
    Delirium and its association with short-term outcomes in younger and older patients with acute heart failure.
    PLoS One. 2022;17:e0270889.
    PubMed         Abstract available

  58. KANG JO, Ha TW, Jung HU, Lim JE, et al
    A cardiac-null mutation of Prdm16 causes hypotension in mice with cardiac hypertrophy via increased nitric oxide synthase 1.
    PLoS One. 2022;17:e0267938.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.